DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
81.01
0.00 (0.00%)
At close: Jun 18, 2025, 4:00 PM
80.99
-0.02 (-0.02%)
Pre-market: Jun 20, 2025, 7:48 AM EDT
DexCom Employees
DexCom had 10,300 employees as of December 31, 2024. The number of employees increased by 700 or 7.29% compared to the previous year.
Employees
10,300
Change (1Y)
700
Growth (1Y)
7.29%
Revenue / Employee
$402,718
Profits / Employee
$51,961
Market Cap
31.76B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10,300 | 700 | 7.29% |
Dec 31, 2023 | 9,600 | 2,000 | 26.32% |
Dec 31, 2022 | 7,600 | 600 | 8.57% |
Dec 31, 2021 | 7,000 | 600 | 9.38% |
Dec 31, 2020 | 6,400 | 1,200 | 23.08% |
Dec 31, 2019 | 5,200 | 1,300 | 33.33% |
Dec 31, 2018 | 3,900 | 910 | 30.43% |
Dec 31, 2017 | 2,990 | 690 | 30.00% |
Dec 31, 2016 | 2,300 | 791 | 52.42% |
Dec 31, 2015 | 1,509 | 448 | 42.22% |
Dec 31, 2014 | 1,061 | 296 | 38.69% |
Dec 31, 2013 | 765 | 67 | 9.60% |
Dec 31, 2012 | 698 | 78 | 12.58% |
Dec 31, 2011 | 620 | 100 | 19.23% |
Dec 31, 2010 | 520 | 135 | 35.06% |
Dec 31, 2009 | 385 | 81 | 26.64% |
Dec 31, 2008 | 304 | 52 | 20.63% |
Dec 31, 2007 | 252 | -8 | -3.08% |
Dec 31, 2006 | 260 | 105 | 67.74% |
Dec 31, 2005 | 155 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
DXCM News
- 1 day ago - Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025 - Business Wire
- 9 days ago - Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - Business Wire
- 15 days ago - Jefferies' high conviction US stocks for the summer: Nvidia among top picks - Invezz
- 5 weeks ago - Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO - Business Wire
- 5 weeks ago - DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure - Seeking Alpha
- 6 weeks ago - DexCom: Growth Is Reaccelerating But Don't Ignore The Risks - Seeking Alpha
- 6 weeks ago - Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism - FXEmpire
- 6 weeks ago - Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring. - Barrons